Rice lab’s injectable gel feeds steady dose of drugs to tumor cells
An immunotherapy drug embedded in a slow-release hydrogel invented at Rice University in collaboration with the University of Texas Health Science Center at Houston (UTHealth) appears to be highly effective at killing cancer cells.
STINGel combines a new class of immunotherapy drugs called stimulator of interferon gene (STING) agonists with an injectable hydrogel that releases the drug in a steady dose to activate the immune system to kill cancer cells. It was developed by the Rice lab of chemist and bioengineer Jeffrey Hartgerink and Rice alum Simon Young, an assistant professor of oral and maxillofacial surgery at UTHealth.
In clinical trials, immunotherapy drugs have demonstrated strong cancer-fighting abilities. Research has also found that the drugs are flushed quickly from the body, and current trials require multiple injections.
The new research, which is detailed in Biomaterials, showed that slow-release peptide gels could continuously deliver immunotherapy drugs to tumor sites for long periods of time.
Hartgerink is a pioneer in the development of self-assembling multidomain peptide (MDP) hydrogels, which mimic the body’s extracellular matrix to encourage the growth of cells and vascular systems for tissue repair. The hydrogel is injected as a liquid, turns semisolid inside the body and slowly degrades over time.
The hydrogel in the new study is also welcoming to cells, but when the invaders are cancer cells, they’re in for trouble. Immunotherapy drugs known as cyclic dinucleotides (CDNs) await them inside the gel.
Hartgerink, a professor of chemistry and bioengineering, said the concentration of CDN in the hydrogel is important.
“The normal approach to CDN delivery is simple injection, but this leads to very rapid diffusion of the drug throughout the body and reduces its concentration at the site of the tumor to very low levels,” he said. “Using the same amount of CDN, the STINGel approach allows the concentration of CDN near the tumor to remain much higher for long periods of time.”
STINGel was studied both in lab cultures and in vivo. For the in vivo portion, six groups of 10 rodents each were treated with CDN alone, control collagens alone or with CDN, MDP alone or STINGel (CDN plus MDP). Only one in 10 CDN or collagen plus CDN animals survived 105 days, but six of 10 animals treated with STINGel survived. These also proved resistant to further implantation of cancer cells, meaning their immune systems were trained to successfully identify and destroy both the existing cancer and future occurrence of that cancer, Hartgerink said.
The lab tested more common hydrogels but found that they were unable to provide the same controlled release and also failed to provide an additional benefit over CDN treatment seen in clinical trials. “The MDP hydrogel provides a unique environment for the release of CDN that other gels just can’t match,” Hartgerink said.
“The CDN we used in this study is currently in clinical trials,” he said. “We think that our STINGel approach has the potential to significantly broaden the scope of this powerful immunotherapy drug to a larger range of resistant cancers.”
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- Uma Thurman invests in cancer immunotherapy companyon January 13, 2021 at 11:04 am
Sensei Biotherapeutics, a clinical-stage cancer immunotherapy company that opened a Boston R&D hub last year, has attracted high-profile investors for its $30 million Series B round.
- Americas Cancer Immunotherapy Market with Focus on Growth Analysis, Key Vendors, Emerging Technologies and Recent Trends by Forecast to 2023on January 13, 2021 at 10:22 am
The Americas cancer immunotherapy market is expected to grow at an approximate CAGR of 10.1% during the forecast period. Browse Sample of the Report @ The Americas cancer immunotherapy market is ...
- UPMC Enterprises spinout focused on cancer treatments raises $45Mon January 13, 2021 at 10:18 am
BlueSphere Bio is using the novel TCXpress technology platform to create personalized therapies developed with a patient’s own T-cells.
- Treating cancer with precision: It’s time for host response profilingon January 13, 2021 at 8:03 am
Host response can be identified by proteomic profiling, which involves analyzing a broad range of select proteins in a series of patient blood samples, with the first collected prior to treatment and ...
- MD Anderson and UroGen Pharma announce strategic research collaboration to advance investigational treatment for high-grade bladder canceron January 13, 2021 at 5:57 am
MD Anderson and UroGen today announced a strategic three-year collaboration agreement to advance combination immunotherapy, delivered directly into the bladder, for the treatment of high-grade ...
- Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidateon January 12, 2021 at 10:50 pm
PRNewswire/ -- Dragonfly Therapeutics (“Dragonfly”), a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, today announced that AbbVie (NYSE: ...
- Understanding how to improve antibodies targeting OX40 for the treatment of canceron January 12, 2021 at 6:29 pm
Scientists have gained new insight into how the immune system can be better used to find and kill cancer cells.
- Researchers identify new gene involved in breast cancer growthon January 12, 2021 at 10:09 am
A team of UT Southwestern researchers has identified a gene involved in the growth of breast cancer, a finding that could lead to potential new targets for treatment.
- Novartis, once wary of Chinese M&A, dives into BeiGene's cancer immunotherapyon January 12, 2021 at 4:20 am
Swiss drugmaker Novartis paid $650 million to snag an immuno-oncology drug from BeiGene Ltd, the latest Western drugmaker turning to China for must-have assets to fill holes in their cancer portfolios ...
- Cancer Immunotherapy Market Analysis with Key Players, Applications, Trends and Forecasts to 2025on January 11, 2021 at 3:45 am
Global Cancer Immunotherapy Market is anticipated to grow at a CAGR of around 13% during 2020-25. Cancer immunotherapy has its extensive utilization in the treatment of blood cancer, prostate cancer, ...
via Bing News